It has also been shown that treatment of mice with the RIPK1-inhibitor necrostatin-1 (Nec-1s) or endothelial-cell-specific deletion of RIPK3 reduced tumor cell-induced endothelial necroptosis and tumor metastasis in mouse models [140]. This evidence concerns the gene RIPK3 and neoplasm.